Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period from November 1, 2012, to May 13, 2013. The document serves as a Block Listing Six Monthly Return, detailing the status of various share option and savings-related share option schemes. It is not a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation scheme mechanics.
| Scheme Name | Securities Issued/Allotted (Period) | Balance Unallotted (End of Period) |
|---|---|---|
| GlaxoSmithKline Share Option Plan – Ordinary Shares | 11,294,858 | 8,422,343 |
| GlaxoSmithKline Share Option Plan - ADS | 14,701,554 | 8,660,524 |
| Glaxo Wellcome UK Share Option Scheme | 0 | 5,119,750 |
| Glaxo Wellcome International Share Option Scheme | 0 | 13,267,156 |
| Glaxo Wellcome 1999 Share Option Plan | 0 | 1,040,000 |
| SmithKline Beecham 1989 Executive Share Option Plan (Approved) | 0 | 163,606 |
| SmithKline Beecham 1989 Executive Share Option Plan (Unapproved - ADS) | 0 | 275,420 |
| SmithKline Beecham 1989 Executive Share Option Plan (Unapproved - Ordinary) | 0 | 100,000 |
| GlaxoSmithKline Savings Related Share Option Scheme | 1,077,551 | 2,812,430 |
| GlaxoSmithKline plc Sharesave plan 2012 | 4 | 4,996 |
Material Changes
- Block Increases: The "GlaxoSmithKline Share Option Plan – Ordinary Shares" increased its block by 10,000,000 securities. The "GlaxoSmithKline Share Option Plan - ADS" increased its block by 15,000,000 securities. The "GlaxoSmithKline plc Sharesave plan 2012" increased by 5,000 securities.
- Issuance Activity: Significant issuance occurred in the primary Share Option Plans (Ordinary and ADS) and the Savings Related Share Option Scheme. No securities were issued under the legacy Glaxo Wellcome or SmithKline Beecham schemes during this period.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory compliance report regarding share scheme balances.
Investor Verification Checklist
- Verify the total number of shares issued under the primary Share Option Plans (Ordinary and ADS) against the company's latest equity compensation expense reports.
- Confirm the impact of the 25,000,000 combined block increase on potential future dilution.
- Review the status of legacy schemes (Glaxo Wellcome and SmithKline Beecham) to confirm they remain inactive with zero issuances.
- Check the authorized signatory details (Victoria Whyte) against current corporate governance records.